Unity towards the Future | Dr. Cui Jisong, Chairman and CEO of Nuocheng Jianhua, delivers a New Year

Joining Hands for the Future | Dr. Cui Jisong, Chairman and CEO of Nuocheng Jianhua, delivers a New Year's speech in two thousand twenty-five. As the year progresses, Huazhang is constantly updated. Faced with the ever-changing market environment, Nuocheng Jianhua has always faced difficulties and achieved remarkable results. Behind every breakthrough lies the persistence and dedication of all employees and partners of the company; Every achievement is the best interpretation of how we use innovation to light up our lives.; two thousand twenty-four is the first year of the rapid development stage of Nuocheng Jianhua two.zero. Our original intention remains the same, walking towards the light.; This year, our commercial growth has continued to accelerate, constantly raising sales guidelines for the BTK inhibitor Obutinib. Obutinib's new indication for borderline lymphoma has been rapidly increasing since its inclusion in medical insurance in two thousand twenty-three. At the same time, the company has built a more experienced team for commercializing blood tumors, demonstrating strong execution capabilities.; This year, our R&D pipeline has continuously made breakthroughs and worked tirelessly to benefit patients. The marketing application for CDnineteen Tanxitumab has been accepted and included in the priority review in China, and the marketing application for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma with Obutinib has been accepted. We all look forward to being approved for marketing next year; The TRK inhibitor Zurletrectinib has entered the preparation stage for new drug marketing applications and will submit the marketing application in the first quarter of next year.; This year, our six major indications for autoimmune diseases are poised to take off. Obutinib has been approved by the US FDA to conduct a phase III clinical trial for the treatment of primary progressive multiple sclerosis; The Phase III clinical trial of TYKtwo inhibitor soficitinib (ICP-three hundred and thirty-two) for the treatment of atopic dermatitis has been successfully launched, and the new indication vitiligo has been approved for clinical use; The Phase II clinical data of ICP-four hundred and eighty-eight treatment for psoriasis is impressive, and the Phase III clinical launch is imminent.; two thousand twenty-five is the tenth year in the development process of Nuocheng Jianhua. We will stand at a new starting point, unwaveringly lead a healthy future with outstanding innovation.; We must continue to maintain the spirit of entrepreneurship and innovation, and create infinite possibilities on the road of new drug research and development. Every goal we set is a commitment to science, a commitment to patients, and a determination to drive industry development.; We will accelerate research and development, commercialization, and globalization, which are the answers we must deliver in the two.zero phase. It is expected that five to six innovative drugs will be approved for market in the next three to five years, and three to four products will enter internationalization to achieve the company's two.zero development goal.; The road ahead may be full of challenges, but I firmly believe that as long as all of us at Nuocheng Jianhua join hands and work together, there will be no difficulties that cannot be overcome. On the journey of illuminating the light of human life, let us always maintain our original intention and work together towards the future!; Finally, I sincerely wish everyone all the best and happiness in two thousand twenty-five!